Pharmacogenetics of antidepressant medication intolerance

American Journal of Psychiatry

Volumn 160, Issue 10, 2003, Pages 1830-1835

  Murphy Jr , Greer M ^a   Kremer, Charlotte ^a   Rodrigues, Heidi E ^a   Schatzberg, Alan F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; CYTOSINE; DRUG DERIVATIVE; MIANSERIN; MITOCHONDRIAL PROTEIN; SERINE PROTEINASE; SERINE PROTEINASE OMI; SEROTONIN RECEPTOR; THYMINE;

AGITATION; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; GASTROINTESTINAL SYMPTOM; GENE LOCUS; GENOTYPE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MOOD; PATIENT COMPLIANCE; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; TREATMENT OUTCOME; AGED; DRUG TOLERANCE; FEMALE; GENETIC MARKER; GENETICS; MALE; METABOLISM;

AGED; ALLELES; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP2D6; CYTOSINE; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; MALE; MIANSERIN; MITOCHONDRIAL PROTEINS; PAROXETINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, SEROTONIN; SERINE ENDOPEPTIDASES; SEROTONIN UPTAKE INHIBITORS; THYMINE;

EID: 0642371335     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.10.1830     Document Type: Article

References (30)

1. Bertilsson L, Dahl ML, Tybring G: Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 1997; 391:14-21
2. Cravchik A, Goldman D: Neurochemical individuality: genetic diversity among human dopamine and serotonin receptors and transporters. Arch Gen Psychiatry 2000; 57:1105-1114
3. Access and Utilization of New Antidepressant and Antipsychotic Medications: Report to Office of the Assistant Secretary for Planning and Evaluation, US Department of Heath and Human Services. Washington, DC, US DHHS, Jan 2000
4. Bosker FJ, Klompmakers AA, Westenberg HG: Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat. Neuropharmacology 1995; 34:501-508
5. Malagie I, Deslandes A, Gardier AM: Effects of acute and chronic tianeptine administration on serotonin outflow in rats: comparison with paroxetine by using in vivo microdialysis. Eur J Pharmacol 2000; 403:55-65
6. 2A receptor-like protein in the rat. J Comp Neurol 2000; 418:323-345
7. Janssen P, Prins NH, Meulemans AL, Lefebvre RA: Pharmacological characterization of the 5-HT receptors mediating contraction and relaxation of canine isolated proximal stomach smooth muscle. Br J Pharmacol 2002; 136:321-329
8. Banes A, Florian JA, Watts SW: Mechanisms of 5-hydroxytryptamine(2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther 1999; 291:1179-1187
9. Pullar IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S: LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone. Eur J Pharmacol 2000; 407:39-46
10. Landolt HP, Meier V, Burgess HJ, Finelli LA, Cattelin F, Achermann P, Borbely AA: Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999; 21:455-466
11. Gorzalka BB, Hanson LA, Hong JJ: Ketanserin attenuates the behavioural effects of corticosterone: implications for 5-HT(2A) receptor regulation. Eur J Pharmacol 2001; 428:235-240
12. de Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57(suppl 4):19-25
13. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC, et al: The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51:278-287
14. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28:1168-1175
15. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW: Pharmacogenetic prediction of clozapine response. Lancet 2000; 355:1615-1616
16. 2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999; 24:141-146
17. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, Dorevitch A, Yakir A, Greenberg D, Lerner A, Lerer B: Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001; 6:225-229
18. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
19. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
20. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
21. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10:541-550
22. Murphy GM Jr, Pollock BG, Kirshner MA, Pascoe N, Cneuk W, Mulsant BH, Reynolds CF III: CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 2001; 25:737-743
23. Claassen JD, Pascoe N, Schatzberg AF, Murphy GM Jr: Rapid detection of the C-1496G polymorphism in the CYP2D6 *2 allele. Clin Chem 2001; 47:2153-2155
24. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM: Elucidation of the genetic basis of the common "'intermediate metabolizer" phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10:577-581
25. Sachse C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295
26. Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD: Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet 2000; 96:56-60
27. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983; 17:37-49
28. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F: Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202
29. 2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002; 67:812-822
30. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.